DNA vs GHRS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

DNA

35.0
AI Score
VS
GHRS Wins

GHRS

54.8
AI Score

Investment Advisor Scores

DNA

35score
Recommendation
EXTENDED

GHRS

55score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric DNA GHRS Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth -48.5% 0.0% GHRS
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 35.0/100 54.8/100 GHRS
Profit Margin -219.6% 0.0% GHRS
Beta 1.00 1.00 Tie
AI Recommendation EXTENDED HOLD Tie

Relative Price Performance (Last 90 Days)

DNA 1M: +75.7% · 3M: +22.2% GHRS 1M: -18.3% · 3M: -12.3%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 75

RSI (14): 74.6 · Price: $12.35

GHRS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.4%), weak momentum, RSI 31

RSI (14): 31.0 · Price: $22.94

Fundamentals Snapshot

Metric DNA GHRS
Market Cap — —
Forward P/E -4.3 -12.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.5% 0.0%
Gross Margin 0.7% —
Operating Margin -2.8% 0.0%
EPS -5.19 -0.99
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, GHRS is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.